Page 1

Growth and pipeline progress July - September 2021 Total revenue SEK 3,761 M ( 2,970 ) , +27 per cent , +29 per cent at constant exchange rates ( CER ) Haematology revenue SEK 2,291 M ( 2,147 ) , +9 per cent at CER of which Elocta® SEK 1,035 M ( 1,115 ) , -6 per cent at CER , Alprolix® SEK 430 M ( 435 ) , unchanged at CER , and Doptelet® SEK 400 M ( 145 ) , +187 per cent at CER Immunology revenue SEK 1,144 M ( 619 ) , +89 per cent at CER of which Kineret® SEK 516 M ( 463 ) , +13 per cent at CER , Synagis® SEK 374 M ( 46 ) , +769 per cent at CER , and Gamifant® SEK 255 M ( 110 ) , +139 per cent at CER EBITA¹ SEK 1,166 M ( 933 ) , EBITA margin¹ 31 per cent ( 31 ) Earnings per share ( EPS ) before dilution SEK 1.60 ( 0.94 ) Cash flow from operating activities SEK 257 M ( 381 ) ● ● ● ● January - September 2021 Total revenue SEK 10,633 M ( 10,680 ) , unchanged , +7 per cent at CER Haematology revenue SEK 6,294 M ( 6,578 ) , +1 per cent at CER of which Elocta SEK 2,896 M ( 3,514 ) , -14 per cent at CER , Alprolix SEK 1,281 M ( 1,286 ) , +4 per cent at CER , and Doptelet SEK 810 M ( 396 ) , +126 per cent at CER Immunology revenue SEK 3,450 M ( 3,133 ) , +21 per cent at CER of which Kineret SEK 1,608 M ( 1,493 ) , +16 per cent at CER , Synagis SEK 1,286 M ( 1,294 ) , +13 per cent at CER , and Gamifant SEK 556 M ( 346 ) , +78 per cent at CER EBITA¹ SEK 3,572 M ( 4,124 ) , EBITA margin¹ 34 per cent ( 39 ) EPS before dilution SEK 4.87 ( 5.92 ) Cash flow from operating activities SEK 3,349 M ( 4,209 ) ● sobi rare strength ● ● ● Significant events after the reporting period Aspaveli® ( pegcetacoplan ) for PNH : positive CHMP opinion in the EU 2021 outlook - refined Revenue for the full year 2021 is expected to be in the range of SEK 14,500-15,000 M EBITA margin is expected to be in the range of 33-35 per cent of revenue Financial summary SEK M Total revenue Gross profit Gross margin¹ EBITA¹ EBITA adjusted ¹ , 2 EBITA margin¹ EBITA margin adjusted ¹ , 2 Profit for the period Earnings per share , before dilution , SEK Earnings per share , before dilution , SEK 1,2,3 adjusted ¹ , Q3 2021 1 SOBI Q3 REPORT 2021 3,761 2,802 75 % 1,166 1,166 31 % 31 % 473 1.60 1.60 Q3 2020 2,970 2,339 79 % 933 933 31 % 31 % 278 0.94 0.94 Change 27 % 20 % 25 % 25 % 70 % 70 % 70 % Jan - Sep 2021 10,633 8,165 77 % 3,572 3,572 34 % 34 % 1,438 4.87 4.87 Alternative Performance Measures ( APMs ) , see page 20 for further information . ²EBITA in 2020 excluding non - recurring items ; other operating income related to the reversal of the CVR liability of SEK 399 M. ³EPS in full - year 2020 excluding the reversal of the CVR liability of SEK 399 M. Total revenue Q3 , SEK M 3,761 Total revenue growth Q3 , CER 29 % EBITA margin¹ Q3 31 % Jan - Sep 2020 Q3 2021 report 10,680 8,318 78 % 4,124 4,124 39 % 39 % 1,743 5.92 5.92 Change 0 % -2 % -13 % -13 % -18 % -18 % -18 % Full - year 2020 15,261 12,036 79 % 6,700 6,301 44 % 41 % 3,245 11.01 9.66